Royal London Asset Management Ltd. Sells 338,559 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Royal London Asset Management Ltd. decreased its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 81.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 76,557 shares of the medical research company's stock after selling 338,559 shares during the period. Royal London Asset Management Ltd.'s holdings in IQVIA were worth $15,044,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the company. Synergy Asset Management LLC purchased a new position in IQVIA in the 4th quarter worth approximately $33,000. Avior Wealth Management LLC lifted its holdings in shares of IQVIA by 117.6% in the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company's stock worth $38,000 after buying an additional 87 shares in the last quarter. Versant Capital Management Inc boosted its position in shares of IQVIA by 46.0% during the fourth quarter. Versant Capital Management Inc now owns 295 shares of the medical research company's stock worth $58,000 after acquiring an additional 93 shares during the last quarter. SBI Securities Co. Ltd. bought a new stake in IQVIA in the 4th quarter valued at $60,000. Finally, UMB Bank n.a. lifted its stake in IQVIA by 72.8% in the 4th quarter. UMB Bank n.a. now owns 401 shares of the medical research company's stock worth $79,000 after purchasing an additional 169 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors.

IQVIA Trading Down 2.7 %

IQV traded down $5.04 on Tuesday, reaching $181.07. 1,566,007 shares of the company traded hands, compared to its average volume of 1,241,421. The company has a market cap of $31.93 billion, a P/E ratio of 24.14, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a one year low of $179.28 and a one year high of $253.84. The firm has a fifty day simple moving average of $194.24 and a two-hundred day simple moving average of $207.29.

Remove Ads

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, equities research analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on IQV shares. Robert W. Baird reduced their target price on IQVIA from $212.00 to $210.00 and set a "neutral" rating on the stock in a report on Tuesday, January 21st. Bank of America cut their target price on shares of IQVIA from $255.00 to $235.00 and set a "buy" rating for the company in a report on Friday, December 13th. JPMorgan Chase & Co. decreased their price target on shares of IQVIA from $240.00 to $232.00 and set an "overweight" rating on the stock in a research note on Tuesday, February 18th. Barclays dropped their price objective on shares of IQVIA from $255.00 to $235.00 and set an "overweight" rating for the company in a research note on Monday, February 3rd. Finally, Stifel Nicolaus lowered their price target on shares of IQVIA from $273.00 to $261.00 and set a "buy" rating for the company in a report on Friday, February 7th. Five investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $249.05.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.